Dhaval Desai, PharmD
Chief Development Officer
Dhaval Desai, PharmD joined 4DMT in 2024 as Chief Development Officer. He has spent the past 20+ years working in all aspects of drug development with a focus on clinical development and medical affairs.
Prior to joining 4DMT Dr. Desai was SVP and Chief Development Officer at Iveric Bio where he led the clinical development, medical affairs, and biostatistics departments responsible for the approval and launch of IZERVAY (avacincaptad pegol), one of the first complement inhibitors approved for the treatment of geographic atrophy. Before Iveric, Dr. Desai served as VP and Medical Unit Head of Ophthalmology at Novartis Pharmaceuticals, overseeing both the posterior and anterior segment therapeutic portfolio. In addition, to these roles Dr. Desai has also held leadership positions at other ophthalmology-focused biotech companies including Aerpio Therapeutics and ThromboGenics.
Dr. Desai received his PharmD from and completed a post-doctoral industry fellowship at Rutgers University.